O’Melveny & Myers LLP advised Akeso Biopharma (Akeso) in its recent listing and IPO on the Hong Kong Stock Exchange, while Davis Polk advised the underwriters….
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
